Global installations of Augmented Breast Ultrasound System (ABUS) are expected to reach 1,013 units by 2025, according to a new research report by Future Market Insights (FMI). The report titled, “Automated Breast Ultrasound System: Global Industry Analysis and Opportunity Assessment 2015-2025” forecasts the global Augmented Breast Ultrasound System (ABUS) market to be worth US$ 212.4 Mn by 2025.
Increase in prevalence of breast cancer is creating demand for ABUS, owing to which the ABUS market is expected to witness sustained growth during the forecast period. Other key factors driving the augmented breast ultrasound system include growth in the global radiology market, government initiatives in spreading breast cancer awareness, and extensive research and development for enhanced imaging techniques.
FMI has identified the factors restraining the global ABUS market, and the key factors include stringent regulations in many countries on large-scale adoption of automated breast ultrasound imaging techniques, and lack of reimbursement policies and effective insurance cover. High prices of these systems is also restraining their adoption globally.
FMI has segmented the global ABUS market on the basis of end-users into hospitals and diagnostic imaging laboratories.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-606
The hospital segment of global ABUS market, valued at US$ 48 Mn in 2014, is expected to reach a valuation of US$ 111.4 Mn by 2025. FMI expects this segment to witness a CAGR of over 8% during the forecast period.
Key factors fuelling this segment include government support and emphasis on early detection of cancer, which is expected to lead to increased deployment of these systems across hospitals.
The diagnostic imaging laboratories segment of the global ABUS market is expected to expand at a CAGR of over 8% during the forecast period 2015-2025. Focus on increasing diagnostic laboratories for women in Europe and Asia is anticipated to fuel this segment of the ABUS market.
On the basis of region, FMI has segmented the global augmented breast ultrasound system into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, and Middle East & Africa (MEA).
According to FMI, North America is the most lucrative market for augmented breast ultrasound systems, accounting for 42% share in 2015. FMI expects the ABUS market in the region to gain 430 BPS during the forecast period and account for a market share of 46.1% by 2025.
Western Europe is another key region for ABUS globally, accounting for 32% market share in 2015. FMI expects the ABUS market in Western Europe to lose 330 BPS during the forecast period.
The key players in the global augmented breast ultrasound system market include GE, Siemens, Hitachi, SonoCiné. Among these Siemens was the earliest to foray into ABUS market, launching its first ABUS in 2009. GE entered the ABUS market in 2013, whereas both Hitachi and SonoCiné entered the market in 2014. Hitachi entered the ABUS market in collaboration with Hitachi Aloka, whereas SonoCiné entered the market by forging an agreement with Koninklijke Philips N.V.
Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-gb-606
GE’s product line includes Invenia ABUS, somov. ABUS and somo.v ABUS Platinum, whereas Siemens dominant product is ACUSON S2000 Ultrasound System. Hitachi’s ABUS is known as SOFIA – Automated Breast Tomography System, whereas SonoCine’s product is known as SonoCine’ Automated Whole Breast Ultrasound System.
This post has been seen 199 times.